Orchestra BioMed Q3 2026 Earnings Date & Estimates

Orchestra BioMed (NASDAQ:OBIO) is a clinical-stage biomedical innovation company that develops transformative therapies and medical devices for patients with cardiovascular and other serious medical conditions. The company uses a partnership-driven business model, collaborating with medical device and pharmaceutical companies to advance products through clinical development and toward commercialization.

Its lead programs include Virtue SAB, an investigational drug-device combination designed to deliver sirolimus to the vessel wall without the use of a permanent drug-eluting implant. The product is being developed for vascular applications, including the treatment of stenosis in arteriovenous fistulas used for hemodialysis. Orchestra BioMed is also developing BackBeat Cardiac Neuromodulation Therapy, an investigational device-based treatment intended to provide sustained reductions in blood pressure through electrical modulation of the autonomic nervous system.

Orchestra BioMed was formed through a business combination with ARYA Sciences Acquisition Corp. IV and began trading on the Nasdaq under the symbol OBIO in January 2023. The company is led by founder and Chief Executive Officer David Hochman and conducts its development activities through a combination of internal operations, clinical research organizations and strategic collaborators. Its programs are intended for global markets, with clinical and commercial development supported by international partnerships.